Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

BioXcel Therapeutics is currently studying BXCL501 for potential use in treating acute agitation related to Alzheimer's dementia, as well as agitation linked to bipolar I or II disorder and ...

Enriched with years of accumulated experience with its proprietary computation-based allosteric drug development technology and breakthrough innovation capabilities at Nutshell Therapeutics ...

BioXcel Therapeutics is currently studying BXCL501 for potential use in treating acute agitation related to Alzheimer's dementia, as well as agitation linked to bipolar I or II disorder and ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker.

Enriched with years of accumulated experience with its proprietary computation-based allosteric drug development technology and breakthrough innovation capabilities at Nutshell Therapeutics, NTS071 ...

Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...